Search

Correlation between regular use of medications in the combined cohort of the Prospective Family Study Cohort (N =â 8233). Additional File 1 presents tetrachoric correlations and odds ratios comparing regular use of each of the four medications (aspirin, Cox-2 inhibitors, ibuprofen, and acetaminophen) that were included in the analysis. (DOCX 15 kb)

Purpose Alcohol consumption is an established and important risk factor for breast cancer incidence in the general population. However, the relationship between alcohol and mortality among women with breast cancer is less clear. This study examines the effect of alcohol consumption on mortality in women affected with breast cancer at baseline from a high-risk family breast and ovarian cancer registry. Methods We studied 1116 women affected with breast cancer at baseline from the Metropolitan New York Registry. The examined reported alcohol consumption (total of beer, wine, liquor) was defined as the average number of drinks per week reported from age 12 to age at baseline. We assessed vital status of each participant using participant or family reported data and we used the National Death Index to supplement deaths reported through family updates. We used Cox proportional hazards models to estimate the association between alcohol intake and overall mortality (HRO), breast cancer-specific mortality (HRBC), and non-breast cancer mortality (HRNBC), adjusted for confounders. Results After a mean follow-up of 9.1 years, we observed 211 total deaths and 58 breast cancer deaths. Compared to non-drinkers, we found that both low and moderate to heavy levels of alcohol intake were not associated with greater overall mortality (≤3 drinks/week: HRO: 0.66, 95% CI: 0.38–1.14); > 3 drinks/week: HRO: 1.16, 95% CI: 0.85–1.58), breast cancer–specific mortality (≤ 3 drinks/week: HRBC:0.62, 95% CI: 0.19–2.03; >3 drinks/week: HR BC: 0.96, 95% CI: 0.49–1.89), or non-breast cancer-specific mortality (≤3 drinks/week: HR NBC: 0.73, 95% CI: 0.32–1.6; >3 drinks/week: HRNBC: 1.18, 95% CI: 0.75–1.86). Conclusions Alcohol intake reported from age 12 to age at baseline was not associated with overall or breast cancer-specific mortality in this cohort of affected women with a family history of breast cancer.

Correlation between regular use of medications in the combined cohort of the Prospective Family Study Cohort (N =â 8233). Additional File 1 presents tetrachoric correlations and odds ratios comparing regular use of each of the four medications (aspirin, Cox-2 inhibitors, ibuprofen, and acetaminophen) that were included in the analysis. (DOCX 15 kb)

Additional file 1: Table S1. Adjusted hazard ratios and 95% confidence intervals from Cox proportional hazards modeling of smoking and alcohol variables. Table S2. Adjusted hazard ratios and 95% confidence intervals from Cox proportional hazards modeling of smoking and alcohol variables, excluding BRCA1 and BRCA2 mutation carriers.

Distribution of BOADICEA 1-year risk scores by medication use in the combined cohort of the Prospective Family Study Cohort (NÂ =â 8233). Additional File 2 presents overlapping histograms of the distribution of BOADICEA one-year risk score by medication use (regular users versus non-regular users). (DOCX 45 kb)

BACKGROUND: The association between body mass index (BMI) and risk of breast cancer depends on time of life, but it is unknown whether this association depends on a woman's familial risk. METHODS: We conducted a prospective study of a cohort enriched for familial risk consisting of 16,035 women from 6701 families in the Breast Cancer Family Registry and the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer followed for up to 20 years (mean 10.5 years). There were 896 incident breast cancers (mean age at diagnosis 55.7 years). We used Cox regression to model BMI risk associations as a function of menopausal status, age, and underlying familial risk based on pedigree data using the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA), all measured at baseline. RESULTS: The strength and direction of the BMI risk association depended on baseline menopausal status (P < 0.001); after adjusting for menopausal status, the association did not depend on age at baseline (P = 0.6). In terms of absolute risk, the negative association with BMI for premenopausal women has a much smaller influence than the positive association with BMI for postmenopausal women. Women at higher familial risk have a much larger difference in absolute risk depending on their BMI than women at lower familial risk. CONCLUSIONS: The greater a woman's familial risk, the greater the influence of BMI on her absolute postmenopausal breast cancer risk. Given that age-adjusted BMI is correlated across adulthood, maintaining a healthy weight throughout adult life is particularly important for women with a family history of breast cancer.

Additional file 1: Table S1. Adjusted hazard ratios and 95% confidence intervals from Cox proportional hazards modeling of smoking and alcohol variables. Table S2. Adjusted hazard ratios and 95% confidence intervals from Cox proportional hazards modeling of smoking and alcohol variables, excluding BRCA1 and BRCA2 mutation carriers.

Background The association between body mass index (BMI) and risk of breast cancer depends on time of life, but it is unknown whether this association depends on a woman’s familial risk. Methods We conducted a prospective study of a cohort enriched for familial risk consisting of 16,035 women from 6701 families in the Breast Cancer Family Registry and the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer followed for up to 20 years (mean 10.5 years). There were 896 incident breast cancers (mean age at diagnosis 55.7 years). We used Cox regression to model BMI risk associations as a function of menopausal status, age, and underlying familial risk based on pedigree data using the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA), all measured at baseline. Results The strength and direction of the BMI risk association depended on baseline menopausal status (P

Distribution of BOADICEA 1-year risk scores by medication use in the combined cohort of the Prospective Family Study Cohort (NÂ =â 8233). Additional File 2 presents overlapping histograms of the distribution of BOADICEA one-year risk score by medication use (regular users versus non-regular users). (DOCX 45 kb)